Cream for EGFR inhibitor skin rash
Part of Skin clinical trials.
This trial tests a new cream called ATR04-484 to see if it can help with the painful rash that often appears on the face and chest during EGFR inhibitor cancer treatment. The cream is applied to the skin, with the goal of reducing redness, bumps, and discomfort.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have a moderate to severe rash caused by your EGFR inhibitor cancer treatment, especially on your face.
- You do not have any other major skin disease besides this rash.
- You have not used strong steroid creams, antibiotic creams, or medicated washes on your face, neck, chest, or back in the last 14 days.
- You have not taken oral steroids or oral antibiotics in the last 14 days.
- You do not live with someone who has a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gel (TAR-0520) for treating a bothersome, acne-like rash that often occurs on the face, scalp, or upper chest during cancer treatment with cetuximab or panitumumab. The goal is to see if it helps reduce the rash without affecting your cancer treatment.
This Phase 2 study tests a topical cream (HT-001) to treat skin rashes caused by EGFR inhibitors. It aims to see whether the cream is safe and can reduce rash symptoms and discomfort.
This study tests whether a topical tretinoin cream can prevent the skin rash often caused by anti-EGFR drugs like panitumumab or cetuximab. It is for people with advanced solid tumors who are about to start one of these treatments.
This trial tests an oral drug called erlotinib (an EGFR inhibitor) in adults with certain genetic skin disorders. It aims to reduce symptoms of thickened, blistering or scaly skin. You may be able to join if you have a confirmed genetic form of these conditions and your skin is moderately affected.
This study tests a moisturizing cream (with pre- and postbiotics and niacinamide) to see if it reduces dryness and itching in cancer patients who are on a type of targeted therapy called anti-EGFR drugs. If you have dry, itchy skin from your treatment, this cream might help soothe it.
This study tests whether a new foam treatment (roflumilast) can safely reduce skin rashes, itching, and other skin problems caused by checkpoint inhibitor cancer drugs. If you've developed these skin side effects from immunotherapy, this trial may help ease your symptoms.
Hear when a new EGFR Inhibitor-associated Rash trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.